# Diverse signaling pathways modulate nuclear receptor complexes

Proceedings of the National Academy of Sciences of the Unite

95, 2920-2925

DOI: 10.1073/pnas.95.6.2920

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Mechanistic concepts in androgen-dependence of prostate cancer. , 1998, 17, 421-427. | | 45 |
| 2 | Interdomain communication regulating ligand binding by PPAR-Î³. Nature, 1998, 396, 377-380. | 13.7 | 331 |
| 3 | Signal-specific co-activator domain requirements for Pit-1 activation. Nature, 1998, 395, 301-306. | 13.7 | 273 |
| 5 | Phase-mapping of periodically domain-inverted LiNbO3 with coherent X-rays. Nature, 1998, 395, 306-306. | 13.7 | 1 |
| 6 | Regulation and regulatory parameters of histone modifications. , 1998, 72, 203-213. | | 87 |
| 7 | Comparison of tamoxifen ligands on estrogen receptor interaction with estrogen response elements. Molecular and Cellular Endocrinology, 1998, 143, 79-90. | 1.6 | 26 |
| 8 | Coactivators and corepressors as mediators of nuclear receptor function: An update. Molecular and Cellular Endocrinology, 1998, 143, 1-7. | 1.6 | 100 |
| 9 | Molecular Mechanism of Androgen Action. Trends in Endocrinology and Metabolism, 1998, 9, 317-324. | 3.1 | 53 |
| 10 | Genistein-Mediated Attenuation of Tamoxifen-Induced Antagonism from Estrogen Receptor-Regulated Genes. Biochemical and Biophysical Research Communications, 1998, 253, 38-43. | 1.0 | 39 |
| 11 | A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor Î³-activating Properties. Journal of Biological Chemistry, 1998, 273, 32679-32684. | 1.6 | 170 |
| 12 | Estrogen Receptor Activation Function 1 Works by Binding p160 Coactivator Proteins. Molecular Endocrinology, 1998, 12, 1605-1618. | 3.7 | 338 |
| 13 | Two Separate NCoR (Nuclear Receptor Corepressor) Interaction Domains Mediate Corepressor Action on Thyroid Hormone Response Elements. Molecular Endocrinology, 1998, 12, 1567-1581. | 3.7 | 62 |
| 14 | Eukaryotic Conditional Expression System. BioTechniques, 1999, 27, 106-110. | 0.8 | 4 |
| 15 | Stimulation of Aromatase P450 Promoter (II) Activity in Endometriosis and Its Inhibition in Endometrium Are Regulated by Competitive Binding of Steroidogenic Factor-1 and Chicken Ovalbumin Upstream Promoter Transcription Factor to the Same cis-Acting Element. Molecular Endocrinology, 1999, 13, 239-253. | 3.7 | 200 |
| 16 | Opposing Effects of Corepressor and Coactivators in Determining the Dose-Response Curve of Agonists, and Residual Agonist Activity of Antagonists, for Glucocorticoid Receptor-Regulated Gene Expression. Molecular Endocrinology, 1999, 13, 2108-2121. | 3.7 | 116 |
| 17 | Comparative Analyses of Mechanistic Differences Among Antiestrogens1. Endocrinology, 1999, 140, 5828-5840. | 1.4 | 214 |
| 18 | A Corepressor and Chicken Ovalbumin Upstream Promoter Transcriptional Factor Proteins Modulate Peroxisome Proliferator-Activated Receptor-Î²2/Retinoid X Receptor Î±-Activated Transcription from the Murine Lipoprotein Lipase Promoter*. Endocrinology, 1999, 140, 1586-1593. | 1.4 | 26 |
| 19 | A Fusion Protein of the Estrogen Receptor (ER) and Nuclear Receptor Corepressor (NCoR) Strongly Inhibits Estrogen-Dependent Responses in Breast Cancer Cells. Molecular Endocrinology, 1999, 13, 2122-2136. | 3.7 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 20 | Interdomain Signaling in a Two-domain Fragment of the Human Glucocorticoid Receptor. Journal of Biological Chemistry, 1999, 274, 24737-24741. | 1.6 | 93 |
| 21 | Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.. Endocrine-Related Cancer, 1999, 6, 271-276. | 1.6 | 31 |
| 22 | Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. Journal of Molecular Endocrinology, 1999, 23, 255-275. | 1.1 | 294 |
| 23 | A role for RNA helicase A in post-transcriptional regulation of HIV type 1. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 709-714. | 3.3 | 140 |
| 24 | Regulation of the Transcriptional Activity of the Peroxisome Proliferator-activated Receptor Î± by Phosphorylation of a Ligand-independent trans-Activating Domain. Journal of Biological Chemistry, 1999, 274, 10505-10510. | 1.6 | 158 |
| 25 | Polyamine biosynthesis inhibitors alter protein-protein interactions involving estrogen receptor in MCF-7 breast cancer cells. Journal of Molecular Endocrinology, 1999, 22, 131-139. | 1.1 | 18 |
| 26 | Nuclear Receptor Coregulators: Cellular and Molecular Biology*. Endocrine Reviews, 1999, 20, 321-344. | 8.9 | 1,501 |
| 27 | Unique forms of human and mouse nuclear receptor corepressor SMRT. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2639-2644. | 3.3 | 156 |
| 28 | A peroxisome proliferator-activated receptor Â ligand inhibits adipocyte differentiation. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 6102-6106. | 3.3 | 323 |
| 29 | Statistical Analysis of Array Expression Data as Applied to the Problem of Tamoxifen Resistance. Journal of the National Cancer Institute, 1999, 91, 453-459. | 3.0 | 182 |
| 30 | Identification of Nuclear Receptor Corepressor as a Peroxisome Proliferator-activated Receptor Î± Interacting Protein. Journal of Biological Chemistry, 1999, 274, 15901-15907. | 1.6 | 117 |
| 31 | Estrogen receptor (ER) modulators each induce distinct conformational changes in ER Â and ER Â. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3999-4004. | 3.3 | 397 |
| 32 | Direct Visualization of the Human Estrogen Receptor Î± Reveals a Role for Ligand in the Nuclear Distribution of the Receptor. Molecular Biology of the Cell, 1999, 10, 471-486. | 0.9 | 233 |
| 33 | The Estrogen Receptor Enhances AP-1 Activity by Two Distinct Mechanisms with Different Requirements for Receptor Transactivation Functions. Molecular Endocrinology, 1999, 13, 1672-1685. | 3.7 | 343 |
| 34 | Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature, 1999, 401, 173-177. | 13.7 | 808 |
| 35 | Saccharomyces cerevisiae telomerase is an Sm small nuclear ribonucleoprotein particle. Nature, 1999, 401, 177-180. | 13.7 | 256 |
| 40 | Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev. Nature Medicine, 1999, 5, 635-642. | 15.2 | 152 |
| 41 | An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cellular and Molecular Life Sciences, 1999, 55, 932. | 2.4 | 173 |

| # | Article | IF | Citations |
|---|---|---|---|
| 42 | Orphan Nuclear Receptors: From Gene to Function*. Endocrine Reviews, 1999, 20, 689-725. | 8.9 | 630 |
| 43 | Cell Membrane and Nuclear Estrogen Receptors (ERs) Originate from a Single Transcript: Studies of ERÎ± and ERÎ² Expressed in Chinese Hamster Ovary Cells. Molecular Endocrinology, 1999, 13, 307-319. | 3.7 | 896 |
| 44 | Ligand-independent Activation of Steroid Receptors: New Roles for Old Players. Trends in Endocrinology and Metabolism, 1999, 10, 41-46. | 3.1 | 108 |
| 45 | The Molecular Pharmacology of SERMs. Trends in Endocrinology and Metabolism, 1999, 10, 301-311. | 3.1 | 260 |
| 46 | Evolving Concepts of Selective Estrogen Receptor Action: From Basic Science to Clinical Applications. Trends in Endocrinology and Metabolism, 1999, 10, 299-300. | 3.1 | 22 |
| 47 | Ligand-Independent Recruitment of SRC-1 to Estrogen Receptor Î² through Phosphorylation of Activation Function AF-1. Molecular Cell, 1999, 3, 513-519. | 4.5 | 424 |
| 48 | Phosphorylation of the Nuclear Receptor SF-1 Modulates Cofactor Recruitment. Molecular Cell, 1999, 3, 521-526. | 4.5 | 358 |
| 49 | Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Molecular and Cellular Endocrinology, 1999, 156, 85-93. | 1.6 | 87 |
| 50 | The localization and interactions of huntingtin. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 1021-1027. | 1.8 | 19 |
| 51 | Nuclear-Receptor Ligands and Ligand-Binding Domains. Annual Review of Biochemistry, 1999, 68, 559-581. | 5.0 | 326 |
| 52 | Human Genes Involved in Chromatin Remodeling in Transcription Initiation, and Associated Diseases: An Overview Using the GENATLAS Database. Molecular Genetics and Metabolism, 1999, 67, 261-277. | 0.5 | 11 |
| 53 | The peroxisome proliferator-activated receptorÎ³ (PPARÎ³) as a regulator of monocyte/macrophage function. Journal of Leukocyte Biology, 1999, 66, 733-739. | 1.5 | 276 |
| 54 | A Novel Role for Helix 12 of Retinoid X Receptor in Regulating Repression. Molecular and Cellular Biology, 1999, 19, 6448-6457. | 1.1 | 102 |
| 55 | The Androgen Receptor Amino-Terminal Domain Plays a Key Role in p160 Coactivator-Stimulated Gene Transcription. Molecular and Cellular Biology, 1999, 19, 6085-6097. | 1.1 | 245 |
| 56 | Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use. Journal of Clinical Oncology, 2000, 18, 3172-3186. | 0.8 | 317 |
| 57 | Prediction of interaction partners for orphan nuclear receptors by prior-based protein sequence profiles. Journal of Molecular Recognition, 2000, 13, 117-126. | 1.1 | 0 |
| 58 | An issue of tissues: divining the split personalities of selective estrogen receptor modulators. Nature Medicine, 2000, 6, 960-962. | 15.2 | 61 |
| 59 | The dual function steroid receptor coactivator/ubiquitin protein-ligase integrator E6-AP is overexpressed in mouse mammary tumorigenesis. Breast Cancer Research and Treatment, 2000, 62, 185-195. | 1.1 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 60 | The role of coactivators and corepressors in the biology and mechanism of action of steroid hormone receptors. Journal of Mammary Gland Biology and Neoplasia, 2000, 5, 307-324. | 1.0 | 121 |
| 61 | Estrogen receptor alpha in human breast cancer: occurrence and significance. , 2000, 5, 271-281. | | 264 |
| 62 | Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. British Journal of Cancer, 2000, 82, 501-513. | 2.9 | 93 |
| 63 | Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. British Journal of Cancer, 2000, 82, 1844-1850. | 2.9 | 19 |
| 64 | Formation of a Powerful Capping Motif Corresponding to Start of "Helix 12" in Agonist-Bound Estrogen Receptor-Î± Contributes to Increased Constitutive Activity of the Protein. Cell Biochemistry and Biophysics, 2000, 33, 53-62. | 0.9 | 15 |
| 65 | Molecular Pharmacology of Estrogen and Progesterone Receptors. , 2000, , 3-11. | | 1 |
| 66 | Phosphorylation of Steroid Receptor Coactivator-1. Journal of Biological Chemistry, 2000, 275, 4475-4483. | 1.6 | 235 |
| 67 | DAX-1 Functions as an LXXLL-containing Corepressor for Activated Estrogen Receptors. Journal of Biological Chemistry, 2000, 275, 39855-39859. | 1.6 | 151 |
| 68 | The histone deacetylase-3 complex contains nuclear receptor corepressors. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 7202-7207. | 3.3 | 321 |
| 69 | Tamoxifen-Bound Estrogen Receptor (ER) Strongly Interacts with the Nuclear Matrix Protein HET/SAF-B, a Novel Inhibitor of ER-Mediated Transactivation. Molecular Endocrinology, 2000, 14, 369-381. | 3.7 | 89 |
| 70 | Nuclear Hormone Receptor Coregulators In Action: Diversity For Shared Tasks. Molecular Endocrinology, 2000, 14, 329-347. | 3.7 | 350 |
| 71 | Selection of Estrogen Receptor Î²- and Thyroid Hormone Receptor Î²-Specific Coactivator-Mimetic Peptides Using Recombinant Peptide Libraries. Molecular Endocrinology, 2000, 14, 605-622. | 3.7 | 44 |
| 72 | Characterization of Transactivational Property and Coactivator Mediation of Rat Mineralocorticoid Receptor Activation Function-1 (AF-1). Molecular Endocrinology, 2000, 14, 889-899. | 3.7 | 74 |
| 73 | Development of Peptide Antagonists That Target Estrogen Receptor Î²-Coactivator Interactions. Molecular Endocrinology, 2000, 14, 2010-2023. | 3.7 | 69 |
| 74 | The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export. Molecular and Cellular Biology, 2000, 20, 6612-6625. | 1.1 | 166 |
| 75 | Ecdysone receptors and their biological actions. Vitamins and Hormones, 2000, 60, 1-73. | 0.7 | 469 |
| 76 | A Tissue-Specific Coactivator of Steroid Receptors, Identified in a Functional Genetic Screen. Molecular and Cellular Biology, 2000, 20, 2411-2422. | 1.1 | 286 |
| 77 | Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Human Molecular Genetics, 2000, 9, 267-274. | 1.4 | 227 |

| # | Article | IF | Citations |
|---|---|---|---|
| 78 | Steroid hormone receptors: an update. Human Reproduction Update, 2000, 6, 225-236. | 5.2 | 512 |
| 79 | Modulation of Estrogen Receptor-Î± Transcriptional Activity by the Coactivator PGC-1. Journal of Biological Chemistry, 2000, 275, 16302-16308. | 1.6 | 193 |
| 80 | Cell Signaling Switches HOX-PBX Complexes from Repressors to Activators of Transcription Mediated by Histone Deacetylases and Histone Acetyltransferases. Molecular and Cellular Biology, 2000, 20, 8623-8633. | 1.1 | 179 |
| 81 | Recruitment of Nuclear Receptor Corepressor and Coactivator to the Retinoic Acid Receptor by Retinoid Ligands. Journal of Biological Chemistry, 2000, 275, 19401-19408. | 1.6 | 35 |
| 82 | An Antiestrogen-responsive Estrogen Receptor-Î± Mutant (D351Y) Shows Weak AF-2 Activity in the Presence of Tamoxifen. Journal of Biological Chemistry, 2000, 275, 37552-37558. | 1.6 | 24 |
| 83 | Association with Ets-1 Causes Ligand- and AF2-Independent Activation of Nuclear Receptors. Molecular and Cellular Biology, 2000, 20, 8793-8802. | 1.1 | 49 |
| 84 | 8-Bromo-Cyclic AMP Induces Phosphorylation of Two Sites in SRC-1 That Facilitate Ligand-Independent Activation of the Chicken Progesterone Receptor and Are Critical for Functional Cooperation between SRC-1 and CREB Binding Protein. Molecular and Cellular Biology, 2000, 20, 8720-8730. | 1.1 | 226 |
| 85 | A Dominant-negative Peroxisome Proliferator-activated Receptor Î³ (PPARÎ³) Mutant Is a Constitutive Repressor and Inhibits PPARÎ³-mediated Adipogenesis. Journal of Biological Chemistry, 2000, 275, 5754-5759. | 1.6 | 249 |
| 86 | A Novel Nuclear Receptor Corepressor Complex, N-CoR, Contains Components of the Mammalian SWI/SNF Complex and the Corepressor KAP-1. Journal of Biological Chemistry, 2000, 275, 40463-40470. | 1.6 | 279 |
| 87 | Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry and Molecular Biology, 2000, 74, 311-317. | 1.2 | 785 |
| 88 | Development of peptide antagonists that target estrogen receptorâ€“cofactor interactions. Journal of Steroid Biochemistry and Molecular Biology, 2000, 74, 327-335. | 1.2 | 36 |
| 89 | Transcriptional Repression by Nuclear Hormone Receptors. Trends in Endocrinology and Metabolism, 2000, 11, 6-10. | 3.1 | 268 |
| 90 | Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids, 2000, 65, 579-584. | 0.8 | 52 |
| 91 | Estrogen receptor interaction with co-activators and co-repressorsâ˜†. Steroids, 2000, 65, 227-251. | 0.8 | 413 |
| 92 | Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development. Cell, 2000, 102, 753-763. | 13.5 | 475 |
| 93 | Cofactor Dynamics and Sufficiency in Estrogen Receptorâ€“Regulated Transcription. Cell, 2000, 103, 843-852. | 13.5 | 1,571 |
| 94 | Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Research, 2000, 2, 335-44. | 2.2 | 236 |
| 95 | Single-Tube Gene-Specific Expression Analysis by High Primer Density Multiplex Reverse Transcription. Molecular Genetics and Metabolism, 2001, 74, 435-448. | 0.5 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 96 | Molecular and pharmacological aspects of antiestrogen resistance. Journal of Steroid Biochemistry and Molecular Biology, 2001, 76, 71-84. | 1.2 | 125 |
| 97 | Contribution of steroid receptor coactivator-1 and CREB binding protein in ligand-independent activity of estrogen receptor Î². Journal of Steroid Biochemistry and Molecular Biology, 2001, 77, 19-27. | 1.2 | 64 |
| 98 | Estrogen receptor antibodies: specificity and utility in detection, localization and analyses of estrogen receptor Î± and Î². Steroids, 2001, 66, 1-16. | 0.8 | 83 |
| 99 | Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor Î±. Journal of Biological Chemistry, 2001, 276, 9817-9824. | 1.6 | 831 |
| 100 | Proteins Accompanying the Estrogen Receptor Î± and Î²: A Model for Studying Protein Hetero-Complexes. Biocatalysis and Biotransformation, 2001, 19, 427-442. | 1.1 | 2 |
| 101 | Structureâ^'Function Evaluation of ER Î± and Î² Interplay with SRC Family Coactivators. ER Selective Ligands. Biochemistry, 2001, 40, 6756-6765. | 1.2 | 102 |
| 102 | Mechanisms of Estrogen Action. Physiological Reviews, 2001, 81, 1535-1565. | 13.1 | 1,671 |
| 103 | Protein coregulators that mediate estrogen receptor function. Reproduction, Fertility and Development, 2001, 13, 221. | 0.1 | 17 |
| 105 | Oestrogen receptors, growth factors and the control of breast cancer. Breast, 2001, 10, 27-35. | 0.9 | 7 |
| 106 | Transcriptional coregulators of the nuclear receptor superfamily: coactivators and corepressors. Cellular and Molecular Life Sciences, 2001, 58, 289-297. | 2.4 | 116 |
| 107 | The pleiotropic functions of peroxisome proliferator-activated receptor Î³. Journal of Molecular Medicine, 2001, 79, 30-47. | 1.7 | 193 |
| 108 | Estrogen receptor and breast cancer. Seminars in Cancer Biology, 2001, 11, 339-352. | 4.3 | 265 |
| 109 | The SMRT corepressor is a target of phosphorylation by protein kinase CK2 (casein kinase II). Molecular and Cellular Biochemistry, 2001, 220, 1-13. | 1.4 | 46 |
| 110 | The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Medicine, 2001, 7, 584-590. | 15.2 | 798 |
| 111 | Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene, 2001, 20, 3047-3054. | 2.6 | 240 |
| 112 | The development of androgen-independent prostate cancer. Nature Reviews Cancer, 2001, 1, 34-45. | 12.8 | 2,057 |
| 113 | Transcriptional activities of estrogen receptor alpha and beta in yeast properties of raloxifene 1 1Abbreviations: ERE, estrogen response element; E2, 17Î²-estradiol; RAL, raloxifene; ERÎ±, estrogen receptor Î±; ERÎ², estrogen receptor Î²; and SERM, selective estrogen receptor modulator.. Biochemical Pharmacology, 2001, 62, 953-961. | 2.0 | 39 |
| 114 | Structural Insights into the Mode of Action of a Pure Antiestrogen. Structure, 2001, 9, 145-153. | 1.6 | 331 |

| # | Article | IF | Citations |
|---|---|---|---|
| 115 | BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9587-9592. | 3.3 | 192 |
| 116 | Ligand- and Coactivator-mediated Transactivation Function (AF2) of the Androgen Receptor Ligand-binding Domain Is Inhibited by the Cognate Hinge Region. Journal of Biological Chemistry, 2001, 276, 7493-7499. | 1.6 | 66 |
| 117 | Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions. Journal of Biological Chemistry, 2001, 276, 27907-27912. | 1.6 | 144 |
| 118 | Arsenic Trioxide Is a Potent Inhibitor of the Interaction of SMRT Corepressor with Its Transcription Factor Partners, Including the PML-Retinoic Acid Receptor Î± Oncoprotein Found in Human Acute Promyelocytic Leukemia. Molecular and Cellular Biology, 2001, 21, 7172-7182. | 1.1 | 59 |
| 119 | Estrogen Receptor Binding to DNA Is Not Required for Its Activity through the Nonclassical AP1 Pathway. Journal of Biological Chemistry, 2001, 276, 13615-13621. | 1.6 | 248 |
| 120 | Agonist-dependent Repression Mediated by Mutant Estrogen Receptor Î± That Lacks the Activation Function 2 Core Domain. Journal of Biological Chemistry, 2001, 276, 37280-37283. | 1.6 | 22 |
| 121 | Coregulator Codes of Transcriptional Regulation by Nuclear Receptors. Journal of Biological Chemistry, 2001, 276, 36865-36868. | 1.6 | 441 |
| 122 | The Tamoxifen-responsive Estrogen Receptor Î± Mutant D351Y Shows Reduced Tamoxifen-dependent Interaction with Corepressor Complexes. Journal of Biological Chemistry, 2001, 276, 42684-42691. | 1.6 | 47 |
| 123 | Peroxisome Proliferator-activated Receptor Î´ (PPARÎ´)-mediated Regulation of Preadipocyte Proliferation and Gene Expression Is Dependent on cAMP Signaling. Journal of Biological Chemistry, 2001, 276, 3175-3182. | 1.6 | 156 |
| 124 | Transactivation Specificity of Glucocorticoid VersusProgesterone Receptors. Journal of Biological Chemistry, 2001, 276, 24806-24816. | 1.6 | 36 |
| 125 | Identification of a Phosphorylation Site in the Hinge Region of the Human Progesterone Receptor and Additional Amino-terminal Phosphorylation Sites. Journal of Biological Chemistry, 2001, 276, 8475-8483. | 1.6 | 92 |
| 126 | Direct Acetylation of the Estrogen Receptor Î± Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity. Journal of Biological Chemistry, 2001, 276, 18375-18383. | 1.6 | 312 |
| 127 | Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. Journal of Molecular Endocrinology, 2001, 27, 1-9. | 1.1 | 225 |
| 128 | Acyl-CoA Esters Antagonize the Effects of Ligands on Peroxisome Proliferator-activated Receptor Î± Conformation, DNA Binding, and Interaction with Co-factors. Journal of Biological Chemistry, 2001, 276, 21410-21416. | 1.6 | 46 |
| 129 | The Human Estrogen Receptor-Î± Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators. Journal of Biological Chemistry, 2001, 276, 35684-35692. | 1.6 | 404 |
| 130 | Multiple Regions of ETO Cooperate in Transcriptional Repression. Journal of Biological Chemistry, 2001, 276, 9889-9895. | 1.6 | 75 |
| 131 | Perspective: Female Steroid Hormone Action. Endocrinology, 2001, 142, 2194-2199. | 1.4 | 55 |
| 132 | New Antiprogestins with Partial Agonist Activity: Potential Selective Progesterone Receptor Modulators (SPRMs) and Probes for Receptor- and Coregulator-Induced Changes in Progesterone Receptor Induction Properties. Molecular Endocrinology, 2001, 15, 255-270. | 3.7 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 133 | Histone Acetylation / Deacetylation and Cancer: An “Open” and “Shut” Case?. Current Molecular Medicine, 2001, 1, 401-429. | 0.6 | 87 |
| 134 | SYNTHETIC RETINOIDS DISSOCIATE COACTIVATOR BINDING FROM COREPRESSOR RELEASE. Journal of Receptor and Signal Transduction Research, 2002, 22, 31-61. | 1.3 | 12 |
| 135 | Chromatin remodeling and tissue-selective responses of nuclear hormone receptors. Biochemistry and Cell Biology, 2002, 80, 343-351. | 0.9 | 35 |
| 136 | Androgen Receptor (AR) Coregulators: An Overview. Endocrine Reviews, 2002, 23, 175-200. | 8.9 | 767 |
| 137 | The PGC-1-related Protein PERC Is a Selective Coactivator of Estrogen Receptor Î±. Journal of Biological Chemistry, 2002, 277, 13918-13925. | 1.6 | 201 |
| 138 | Molecular Cloning and Characterization of CAPER, a Novel Coactivator of Activating Protein-1 and Estrogen Receptors. Journal of Biological Chemistry, 2002, 277, 1229-1234. | 1.6 | 92 |
| 139 | Modulation of Induction Properties of Glucocorticoid Receptor-Agonist and -Antagonist Complexes by Coactivators Involves Binding to Receptors but Is Independent of Ability of Coactivators to Augment Transactivation. Journal of Biological Chemistry, 2002, 277, 49256-49266. | 1.6 | 32 |
| 140 | Insulin Induces Heterologous Desensitization of G Protein-Coupled Receptor and Insulin-Like Growth Factor I Signaling by Downregulating Î²-Arrestin-1. Molecular and Cellular Biology, 2002, 22, 6272-6285. | 1.1 | 76 |
| 141 | The Transcription Factor B-Myb Is Maintained in an Inhibited State in Target Cells through Its Interaction with the Nuclear Corepressors N-CoR and SMRT. Molecular and Cellular Biology, 2002, 22, 3663-3673. | 1.1 | 37 |
| 142 | Enhancement of VDR-Mediated Transcription by Phosphorylation: Correlation with Increased Interaction Between the VDR and DRIP205, a Subunit of the VDR-Interacting Protein Coactivator Complex. Molecular Endocrinology, 2002, 16, 301-314. | 3.7 | 78 |
| 143 | Identification of a Negative Regulatory Surface within Estrogen Receptor Î± Provides Evidence in Support of a Role for Corepressors in Regulating Cellular Responses to Agonists and Antagonists. Molecular Endocrinology, 2002, 16, 1778-1792. | 3.7 | 97 |
| 144 | Differences in the Abilities of Estrogen Receptors to Integrate Activation Functions Are Critical for Subtype-Specific Transcriptional Responses. Molecular Endocrinology, 2002, 16, 1810-1827. | 3.7 | 45 |
| 145 | Direct Interactions between Corepressors and Coactivators Permit the Integration of Nuclear Receptor-Mediated Repression and Activation. Molecular Endocrinology, 2002, 16, 1482-1491. | 3.7 | 50 |
| 146 | The Glucocorticoid Receptor: Molecular Mechanism and New Therapeutic Opportunities. Inflammation and Allergy: Drug Targets, 2002, 1, 127-136. | 3.1 | 42 |
| 147 | TR Surfaces and Conformations Required to Bind Nuclear Receptor Corepressor. Molecular Endocrinology, 2002, 16, 271-286. | 3.7 | 96 |
| 148 | Multiple Phosphorylation Events Control Chicken Ovalbumin Upstream Promoter Transcription Factor I Orphan Nuclear Receptor Activity. Molecular Endocrinology, 2002, 16, 1332-1351. | 3.7 | 18 |
| 149 | Reduction of Coactivator Expression by Antisense Oligodeoxynucleotides Inhibits ERÎ± Transcriptional Activity and MCF-7 Proliferation. Molecular Endocrinology, 2002, 16, 253-270. | 3.7 | 65 |
| 150 | Differential Gene Regulation by PPARÎ³ Agonist and Constitutively Active PPARÎ³2. Molecular Endocrinology, 2002, 16, 1040-1048. | 3.7 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 151 | Endometrial nuclear receptor co-factors SRC-1 and N-CoR are increased in human endometrium during menstruation. Molecular Human Reproduction, 2002, 8, 644-650. | 1.3 | 33 |
| 152 | Deregulated MAPK Activity Prevents Adipocyte Differentiation of Fibroblasts Lacking the Retinoblastoma Protein. Journal of Biological Chemistry, 2002, 277, 26335-26339. | 1.6 | 34 |
| 153 | Novel Mechanism of Nuclear Receptor Corepressor Interaction Dictated by Activation Function 2 Helix Determinants. Molecular and Cellular Biology, 2002, 22, 6831-6841. | 1.1 | 88 |
| 154 | A Structural Model of the Constitutive Androstane Receptor Defines Novel Interactions That Mediate Ligand-Independent Activity. Molecular and Cellular Biology, 2002, 22, 5270-5280. | 1.1 | 105 |
| 155 | Genetic engineering of the glucocorticoid receptor by fusion with the herpes viral protein VP22 causes selective loss of transactivation. Journal of Endocrinology, 2002, 172, 615-625. | 1.2 | 9 |
| 156 | RU486-induced Glucocorticoid Receptor Agonism Is Controlled by the Receptor N Terminus and by Corepressor Binding. Journal of Biological Chemistry, 2002, 277, 26238-26243. | 1.6 | 126 |
| 157 | Developmentally Regulated N-terminal Variants of the Nuclear Receptor Hepatocyte Nuclear Factor 4Î± Mediate Multiple Interactions through Coactivator and Corepressor-Histone Deacetylase Complexes. Journal of Biological Chemistry, 2002, 277, 44677-44687. | 1.6 | 56 |
| 158 | The Stat5-RARÎ± fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood, 2002, 99, 2647-2652. | 0.6 | 39 |
| 159 | Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor Î´-mediated transactivation. Biochemical Journal, 2002, 363, 157. | 1.7 | 59 |
| 160 | Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor Î´-mediated transactivation. Biochemical Journal, 2002, 363, 157-165. | 1.7 | 88 |
| 161 | The Estrogen-Occupied Estrogen Receptor Functions as a Negative Regulator to Inhibit Cell Proliferation Induced by Insulin/IGF-1: A Cell Context-Specific Antimitogenic Action of Estradiol on Rat Lactotrophs in Culture. Endocrinology, 2002, 143, 2750-2758. | 1.4 | 37 |
| 162 | Tissue-specific estrogenic response and molecular mechanisms. Toxicology Letters, 2002, 127, 217-224. | 0.4 | 114 |
| 163 | The role of transcription factors in allergic inflammation. Journal of Allergy and Clinical Immunology, 2002, 110, 553-564. | 1.5 | 36 |
| 164 | PPARÎ³ANDGLUCOSEHOMEOSTASIS. Annual Review of Nutrition, 2002, 22, 167-197. | 4.3 | 393 |
| 165 | Chemoprevention of Breast Cancer. Drugs and Aging, 2002, 19, 43-78. | 1.3 | 6 |
| 166 | Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators. Cell, 2002, 108, 465-474. | 13.5 | 1,345 |
| 167 | Exchange of N-CoR Corepressor and Tip60 Coactivator Complexes Links Gene Expression by NF-ÎºB and Î²-Amyloid Precursor Protein. Cell, 2002, 110, 55-67. | 13.5 | 543 |
| 168 | Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids, 2002, 67, 15-24. | 0.8 | 155 |

| # | Article | IF | Citations |
|---|---|---|---|
| 169 | Genetic network identification by high density, multiplexed reversed transcriptional (HD-MRT) analysis in steroidogenic axis model cell lines. Molecular Genetics and Metabolism, 2002, 77, 159-178. | 0.5 | 9 |
| 170 | A Dynamic Structural Model for Estrogen Receptor-Î± Activation by Ligands, Emphasizing the Role of Interactions between Distant A and E Domains. Molecular Cell, 2002, 10, 1019-1032. | 4.5 | 114 |
| 171 | Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomedicine and Pharmacotherapy, 2002, 56, 65-77. | 2.5 | 49 |
| 172 | Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. Journal of Steroid Biochemistry and Molecular Biology, 2002, 81, 333-341. | 1.2 | 130 |
| 173 | Design of thyroid hormone receptor antagonists from first principles. Journal of Steroid Biochemistry and Molecular Biology, 2002, 83, 59-73. | 1.2 | 62 |
| 174 | Nuclear receptor coregulators: multiple modes of modification. Trends in Endocrinology and Metabolism, 2002, 13, 55-60. | 3.1 | 302 |
| 175 | Acetylation in hormone signaling and the cell cycle. Cytokine and Growth Factor Reviews, 2002, 13, 259-276. | 3.2 | 45 |
| 176 | Structural regions of ERÎ± critical for synergistic transcriptional responses contain co-factor interacting surfaces. Molecular and Cellular Endocrinology, 2002, 192, 171-185. | 1.6 | 12 |
| 177 | Antiandrogens: selective androgen receptor modulators. Molecular and Cellular Endocrinology, 2002, 198, 97-103. | 1.6 | 61 |
| 178 | I. PPARÎ³ in the gastrointestinal tract: gain or pain?. American Journal of Physiology - Renal Physiology, 2002, 282, G581-G585. | 1.6 | 47 |
| 179 | Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1578, 12-20. | 2.4 | 16 |
| 180 | DNA binding and protein interactions of the AHR/ARNT heterodimer that facilitate gene activation. Chemico-Biological Interactions, 2002, 141, 63-76. | 1.7 | 136 |
| 181 | In vivo test systems for the quantitative and qualitative analysis of the biological activity of phytoestrogens. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 777, 191-202. | 1.2 | 57 |
| 182 | Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews Cancer, 2002, 2, 101-112. | 12.8 | 759 |
| 183 | Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. British Journal of Cancer, 2002, 87, 1411-1416. | 2.9 | 63 |
| 184 | Peroxisome proliferator-activated receptors: Lipid binding proteins controling gene expression. Molecular and Cellular Biochemistry, 2002, 239, 131-138. | 1.4 | 58 |
| 185 | Expression of Sex Steroid Receptors and their Co-Factors in Normal and Malignant Breast Tissue: AIB1 is a Carcinoma-Specific Co-Activator. Breast Cancer Research and Treatment, 2003, 78, 193-204. | 1.1 | 86 |
| 186 | Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer. Journal of the National Cancer Institute, 2003, 95, 353-361. | 3.0 | 717 |

| # | Article | IF | Citations |
|---|---|---|---|
| 187 | A dominant negative PPARÎ³ mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. Diabetologia, 2003, 46, 365-377. | 2.9 | 42 |
| 188 | Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance. Breast Cancer, 2003, 10, 112-119. | 1.3 | 46 |
| 189 | Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast, 2003, 12, 362-367. | 0.9 | 129 |
| 190 | Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor ?. International Journal of Cancer, 2003, 107, 353-358. | 2.3 | 193 |
| 191 | Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: A pilot study. International Journal of Cancer, 2003, 107, 700-706. | 2.3 | 7 |
| 192 | Intranuclear trafficking of transcription factors: Requirements for vitamin D-mediated biological control of gene expression. Journal of Cellular Biochemistry, 2003, 88, 340-355. | 1.2 | 2 |
| 193 | Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. Acta Physiologica Scandinavica, 2003, 178, 425-434. | 2.3 | 144 |
| 194 | Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene, 2003, 22, 7316-7339. | 2.6 | 421 |
| 195 | Effects of Retinoid Ligands on RIP140:Â Molecular Interaction with Retinoid Receptors and Biological Activityâ€. Biochemistry, 2003, 42, 971-979. | 1.2 | 25 |
| 196 | Both N- and C-terminal transactivation functions of DNA-bound ERÎ± are blocked by a novel synthetic estrogen ligand. Biochemical and Biophysical Research Communications, 2003, 312, 656-662. | 1.0 | 28 |
| 197 | Estrogen receptor phosphorylation. Steroids, 2003, 68, 1-9. | 0.8 | 428 |
| 198 | RORÎ± Coordinates Reciprocal Signaling in Cerebellar Development through Sonic hedgehog and Calcium-Dependent Pathways. Neuron, 2003, 40, 1119-1131. | 3.8 | 139 |
| 199 | Ligand-independent coactivation of ERÎ± AF-1 by steroid receptor RNA activator (SRA) via MAPK activation. Journal of Steroid Biochemistry and Molecular Biology, 2003, 85, 123-131. | 1.2 | 59 |
| 200 | Identification of estrogen receptor beta expression in Chinese hamster ovary (CHO) cells and comparison of estrogen-responsive gene transcription in cells adapted to serum-free media. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 41-55. | 1.2 | 13 |
| 201 | p33ING1b stimulates the transcriptional activity of the estrogen receptor Î± via its activation function (AF) 2 domain. Journal of Steroid Biochemistry and Molecular Biology, 2003, 87, 57-63. | 1.2 | 18 |
| 202 | Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Research, 2003, 6, 39-52. | 2.2 | 165 |
| 203 | Subtype Specific Effects of Peroxisome Proliferator-Activated Receptor Ligands on Corepressor Affinity. Biochemistry, 2003, 42, 9278-9287. | 1.2 | 44 |
| 204 | The Interplay between the Glucocorticoid Receptor and Nuclear Factor-Î¹B or Activator Protein-1: Molecular Mechanisms for Gene Repression. Endocrine Reviews, 2003, 24, 488-522. | 8.9 | 808 |

| # | Article | IF | Citations |
|---|---|---|---|
| 205 | Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT. Journal of Biological Chemistry, 2003, 278, 5052-5061. | 1.6 | 154 |
| 206 | Regulation of Nuclear Receptor Transcriptional Activity by a Novel DEAD Box RNA Helicase (DP97). Journal of Biological Chemistry, 2003, 278, 4628-4638. | 1.6 | 55 |
| 207 | Ligand-Independent Interactions of p160/Steroid Receptor Coactivators and CREB-Binding Protein (CBP) with Estrogen Receptor-Î±: Regulation by Phosphorylation Sites in the A/B Region Depends on Other Receptor Domains. Molecular Endocrinology, 2003, 17, 1296-1314. | 3.7 | 133 |
| 208 | Identification of a Novel Testicular Orphan Receptor-4 (TR4)-associated Protein as Repressor for the Selective Suppression of TR4-mediated Transactivation. Journal of Biological Chemistry, 2003, 278, 7709-7717. | 1.6 | 21 |
| 209 | T:G Mismatch-specific Thymine-DNA Glycosylase Potentiates Transcription of Estrogen-regulated Genes through Direct Interaction with Estrogen Receptor Î±. Journal of Biological Chemistry, 2003, 278, 38586-38592. | 1.6 | 108 |
| 210 | Estrogen receptor corepressors -- a role in human breast cancer?. Endocrine-Related Cancer, 2003, 10, 517-536. | 1.6 | 111 |
| 211 | Apoptotic Action of 17Â-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo. Journal of the National Cancer Institute, 2003, 95, 1586-1597. | 3.0 | 140 |
| 212 | Regulation of nuclear receptor and cofactor expression in breast cancer cell lines. European Journal of Endocrinology, 2003, 148, 469-479. | 1.9 | 21 |
| 213 | Full Activation of Estrogen Receptor Î± Activation Function-1 Induces Proliferation of Breast Cancer Cells. Journal of Biological Chemistry, 2003, 278, 26704-26714. | 1.6 | 80 |
| 215 | Nuclear receptor superfamily: Principles of signaling. Pure and Applied Chemistry, 2003, 75, 1619-1664. | 0.9 | 41 |
| 216 | New insights into estrogen receptor function in human breast cancer. Annals of Medicine, 2003, 35, 614-631. | 1.5 | 47 |
| 217 | Differential SERM Effects on Corepressor Binding Dictate ERÎ± Activity in Vivo. Journal of Biological Chemistry, 2003, 278, 6912-6920. | 1.6 | 122 |
| 218 | Contrasting Effects of Prenyltransferase Inhibitors on Estrogen-Dependent Cell Cycle Progression and Estrogen Receptor-Mediated Transcriptional Activity in MCF-7 Cells. Endocrinology, 2003, 144, 989-998. | 1.4 | 18 |
| 219 | Dynamic Inhibition of Nuclear Receptor Activation by Corepressor Binding. Molecular Endocrinology, 2003, 17, 366-372. | 3.7 | 36 |
| 220 | Dominant-Negative Nuclear Receptor Corepressor Relieves Transcriptional Inhibition of Retinoic Acid Receptor but Does Not Alter the Agonist/Antagonist Activities of the Tamoxifen-Bound Estrogen Receptor. Molecular Endocrinology, 2003, 17, 1543-1554. | 3.7 | 14 |
| 221 | Dissociation of Steroid Receptor Coactivator 1 and Nuclear Receptor Corepressor Recruitment to the Human Glucocorticoid Receptor by Modification of the Ligand-Receptor Interface: The Role of Tyrosine 735. Molecular Endocrinology, 2003, 17, 845-859. | 3.7 | 56 |
| 222 | Estrogen receptor action through target genes with classical and alternative response elements. Pure and Applied Chemistry, 2003, 75, 1757-1769. | 0.9 | 17 |
| 223 | Transcriptional regulation of cellular fatty acid homeostasis. Advances in Molecular and Cell Biology, 2003, , 319-336. | 0.1 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 224 | Function and mode of action of nuclear receptors: Estrogen, progesterone, and vitamin D. Pure and Applied Chemistry, 2003, 75, 1671-1683. | 0.9 | 4 |
| 225 | Molecular mechanisms of cross-talk between growth factors and nuclear receptor signaling. Pure and Applied Chemistry, 2003, 75, 1743-1756. | 0.9 | 16 |
| 226 | Estrogen Receptors and Anti-Estrogen Therapies. , 2004, 119, 271-292. | | 1 |
| 227 | Pharmacology of Nuclear Receptorâ€“Coregulator Recognition. Vitamins and Hormones, 2004, 68, 145-183. | 0.7 | 27 |
| 228 | Equilibrium Interactions of Corepressors and Coactivators with Agonist and Antagonist Complexes of Glucocorticoid Receptors. Molecular Endocrinology, 2004, 18, 1376-1395. | 3.7 | 96 |
| 229 | Endocrine therapy and other targeted therapies for metastatic breast cancer. Expert Review of Anticancer Therapy, 2004, 4, 1179-1195. | 1.1 | 9 |
| 230 | ARA67/PAT1 Functions as a Repressor To Suppress Androgen Receptor Transactivation. Molecular and Cellular Biology, 2004, 24, 1044-1057. | 1.1 | 33 |
| 232 | Differential Recruitment of Coregulator Proteins Steroid Receptor Coactivator-1 and Silencing Mediator for Retinoid and Thyroid Receptors to the Estrogen Receptor-Estrogen Response Element by Î²-Estradiol and 4-Hydroxytamoxifen in Human Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 375-383. | 1.8 | 92 |
| 233 | Expression of Nuclear Receptors and Cofacotrs in Human Endometrium and Myometrium. Journal of the Society for Gynecologic Investigation, 2004, 11, 104-112. | 1.9 | 79 |
| 234 | Mechanisms of tamoxifen resistance. Endocrine-Related Cancer, 2004, 11, 643-658. | 1.6 | 523 |
| 235 | Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator. Clinical Cancer Research, 2004, 10, 5403-5417. | 3.2 | 65 |
| 236 | Analysis of co-factor function in a glucocorticoid-resistant small cell carcinoma cell line. Journal of Endocrinology, 2004, 183, 375-383. | 1.2 | 19 |
| 238 | Identification of Tamoxifen-Induced Coregulator Interaction Surfaces within the Ligand-Binding Domain of Estrogen Receptors. Molecular and Cellular Biology, 2004, 24, 3445-3459. | 1.1 | 50 |
| 239 | Recruitment of Distinct Chromatin-modifying Complexes by Tamoxifen-complexed Estrogen Receptor at Natural Target Gene Promoters in Vivo. Journal of Biological Chemistry, 2004, 279, 15050-15058. | 1.6 | 120 |
| 240 | Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors Î± and Î² by coactivators and corepressors. Journal of Molecular Endocrinology, 2004, 33, 387-410. | 1.1 | 173 |
| 241 | Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. Journal of Molecular Endocrinology, 2004, 32, 583-594. | 1.1 | 40 |
| 242 | Selective Estrogen Receptor Modulators. Cancer Research, 2004, 64, 1522-1533. | 0.4 | 321 |
| 243 | Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin). Clinical Cancer Research, 2004, 10, 1409-1420. | 3.2 | 70 |

| # | Article | IF | Citations |
|---|---|---|---|
| 244 | Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators. Endocrine Reviews, 2004, 25, 45-71. | 8.9 | 860 |
| 246 | Estrogen receptor-alpha interaction with the CREB binding protein coactivator is regulated by the cellular environment. Journal of Molecular Endocrinology, 2004, 32, 307-323. | 1.1 | 15 |
| 247 | Liver X receptor-Î± mediates cholesterol efflux in glomerular mesangial cells. American Journal of Physiology - Renal Physiology, 2004, 287, F886-F895. | 1.3 | 48 |
| 248 | Expression of estrogen receptor coregulators in normal and malignant human endometrium. Gynecologic Oncology, 2004, 92, 304-313. | 0.6 | 59 |
| 249 | Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochemical Pharmacology, 2004, 68, 1239-1246. | 2.0 | 56 |
| 250 | Mechanisms responsible for regulation of pyruvate dehydrogenase kinase 4 gene expression. Advances in Enzyme Regulation, 2004, 44, 109-121. | 2.9 | 61 |
| 251 | Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in male rats. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2004, 71, 142-149. | 1.4 | 10 |
| 252 | Cloning and functional characterization of a rat Daxx that functions as a corepressor for the androgen receptor. Cell Biology International, 2004, 28, 609-614. | 1.4 | 3 |
| 253 | Selective oestrogen receptor modulators in desmoid tumours. Expert Opinion on Investigational Drugs, 2004, 13, 1457-1468. | 1.9 | 30 |
| 254 | Molecular Mechanisms, Physiological Consequences and Pharmacological Implications of Estrogen Receptor Action. Molecular Diagnosis and Therapy, 2004, 4, 19-28. | 3.3 | 84 |
| 255 | Estrogen Receptor Mutations in Human Disease. Endocrine Reviews, 2004, 25, 869-898. | 8.9 | 350 |
| 256 | The Role of Corepressors in Transcriptional Regulation by Nuclear Hormone Receptors. Annual Review of Physiology, 2004, 66, 315-360. | 5.6 | 289 |
| 257 | Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2004, 96, 926-935. | 3.0 | 1,048 |
| 258 | SMRT and N-CoR Corepressors Are Regulated by Distinct Kinase Signaling Pathways. Journal of Biological Chemistry, 2004, 279, 54676-54686. | 1.6 | 76 |
| 259 | Androgen Receptor in Prostate Cancer. Endocrine Reviews, 2004, 25, 276-308. | 8.9 | 1,475 |
| 260 | Mini-review: estrogen action in the uterus and insulin-like growth factor-I. Growth Hormone and IGF Research, 2004, 14, 431-435. | 0.5 | 23 |
| 261 | Tamoxifen induces the expression of maspin through estrogen receptor-Î±. Cancer Letters, 2004, 209, 55-65. | 3.2 | 26 |
| 262 | SRA coactivation of estrogen receptor-Î± is phosphorylation-independent, and enhances 4-hydroxytamoxifen agonist activity. Biochemical and Biophysical Research Communications, 2004, 323, 332-338. | 1.0 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 263 | A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene. Molecular and Cellular Endocrinology, 2004, 220, 97-107. | 1.6 | 3 |
| 264 | Immediate early gene X-1 (IEX-1), a hydroxytamoxifen regulated gene with increased stimulation in MCF-7 derived resistant breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2004, 88, 247-259. | 1.2 | 14 |
| 265 | The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood, 2004, 103, 4650-4658. | 0.6 | 42 |
| 266 | Phosphorylation of androgen receptor isoforms. Biochemical Journal, 2004, 383, 267-276. | 1.7 | 46 |
| 267 | Molecular mechanisms of crosstalk between thyroid hormones and estrogens. Current Opinion in Endocrinology, Diabetes and Obesity, 2005, 12, 381-388. | 0.6 | 13 |
| 268 | Nuclear receptors and their coregulators in kidney. Kidney International, 2005, 68, 2444-2461. | 2.6 | 14 |
| 269 | Resistance to endocrine therapy in breast cancer. Cancer Chemotherapy and Pharmacology, 2005, 56, 39-46. | 1.1 | 51 |
| 270 | Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemotherapy and Pharmacology, 2005, 56, 10-20. | 1.1 | 170 |
| 272 | The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1Î±/CXCL12. Carcinogenesis, 2005, 26, 1706-1715. | 1.3 | 61 |
| 273 | The Clinical Relevance of Steroid Hormone Receptor Corepressors: Table 1.. Clinical Cancer Research, 2005, 11, 2822-2831. | 3.2 | 36 |
| 274 | Binding of Estrogen Receptor Î² to Estrogen Response Element in Situ Is Independent of Estradiol and Impaired by Its Amino Terminus. Molecular Endocrinology, 2005, 19, 2696-2712. | 3.7 | 41 |
| 275 | Estrogen down-regulation of the corepressor N-CoR: Mechanism and implications for estrogen derepression of N-CoR-regulated genes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13153-13157. | 3.3 | 79 |
| 276 | Cell Cycle Progression Stimulated by Tamoxifen-Bound Estrogen Receptor-Î± and Promoter-Specific Effects in Breast Cancer Cells Deficient in N-CoR and SMRT. Molecular Endocrinology, 2005, 19, 1543-1554. | 3.7 | 101 |
| 277 | Corepressor Binding to Progesterone and Glucocorticoid Receptors Involves the Activation Function-1 Domain and Is Inhibited by Molybdate. Molecular Endocrinology, 2005, 19, 1483-1500. | 3.7 | 31 |
| 278 | Transcriptional Regulation by Steroid Receptor Coactivator Phosphorylation. Endocrine Reviews, 2005, 26, 393-399. | 8.9 | 147 |
| 279 | The Src Kinase Pathway Promotes Tamoxifen Agonist Action in Ishikawa Endometrial Cells through Phosphorylation-Dependent Stabilization of Estrogen Receptor Î± Promoter Interaction and Elevated Steroid Receptor Coactivator 1 Activity. Molecular Endocrinology, 2005, 19, 732-748. | 3.7 | 84 |
| 280 | LIGAND CONTROL OF COREGULATOR RECRUITMENT TO NUCLEAR RECEPTORS. Annual Review of Physiology, 2005, 67, 309-333. | 5.6 | 239 |
| 281 | Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer. Journal of Clinical Oncology, 2005, 23, 1644-1655. | 0.8 | 91 |

| # | Article | IF | Citations |
|---|---|---|---|
| 282 | Stimulatory Cross-talk between NFAT3 and Estrogen Receptor in Breast Cancer Cells. Journal of Biological Chemistry, 2005, 280, 43188-43197. | 1.6 | 57 |
| 283 | Transcriptional Activities of Retinoic Acid Receptors. Vitamins and Hormones, 2005, 70, 199-264. | 0.7 | 107 |
| 284 | Thyroid hormone can increase estrogen-mediated transcription from a consensus estrogen response element in neuroblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4890-4895. | 3.3 | 33 |
| 285 | Functional interactions with Pit-1 reorganize co-repressor complexes in the living cell nucleus. Journal of Cell Science, 2005, 118, 3277-3288. | 1.2 | 14 |
| 286 | The Nuclear Receptor Corepressors NCoR and SMRT Decrease Peroxisome Proliferator-activated Receptor Î³ Transcriptional Activity and Repress 3T3-L1 Adipogenesis. Journal of Biological Chemistry, 2005, 280, 13600-13605. | 1.6 | 198 |
| 287 | Glucocorticoid Receptor Ligand Binding Domain Is Sufficient for the Modulation of Glucocorticoid Induction Properties by Homologous Receptors, Coactivator Transcription Intermediary Factor 2, and Ubc9. Molecular Endocrinology, 2005, 19, 290-311. | 3.7 | 48 |
| 288 | Molecular insights into endocrine resistance. European Journal of Cancer, Supplement, 2005, 3, 225-236. | 2.2 | 2 |
| 289 | Role of Activation Function Domain-1, DNA Binding, and Coactivator GRIP1 in the Expression of Partial Agonist Activity of Glucocorticoid Receptorâ^'Antagonist Complexes. Biochemistry, 2005, 44, 3547-3561. | 1.2 | 29 |
| 290 | Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 23-37. | 1.2 | 30 |
| 291 | Expression of ZER6 in ERÎ±-Positive Breast Cancer. Journal of Surgical Research, 2005, 126, 86-91. | 0.8 | 10 |
| 292 | Expression of nuclear hormone receptors, their coregulators and type I iodothyronine 5â€²-deiodinase gene in mammary tissue of nonlactating and postlactating rats. Life Sciences, 2005, 77, 2584-2593. | 2.0 | 12 |
| 293 | Corepressor subnuclear organization is regulated by estrogen receptor via a mechanism that requires the DNA-binding domain. Molecular and Cellular Endocrinology, 2005, 231, 33-47. | 1.6 | 12 |
| 294 | A novel pesticide-induced conformational state of the oestrogen receptor ligand-binding domain, detected by conformation-specific peptide binding. FEBS Letters, 2005, 579, 541-548. | 1.3 | 29 |
| 295 | Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy. Journal of Clinical Oncology, 2005, 23, 7721-7735. | 0.8 | 430 |
| 296 | Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine-Related Cancer, 2005, 12, 721-747. | 1.6 | 242 |
| 297 | Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-Î± function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Research, 2005, 7, 205-11. | 2.2 | 62 |
| 298 | Endocrinology and hormone therapy in breast cancer: Selective oestrogen receptor modulators and downregulators for breast cancer â€“ have they lost their way?. Breast Cancer Research, 2005, 7, 119-30. | 2.2 | 35 |
| 301 | Overview of Nomenclature of Nuclear Receptors. Pharmacological Reviews, 2006, 58, 685-704. | 7.1 | 540 |

| # | Article | IF | Citations |
|---|---|---|---|
| 302 | Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer. Topics in Medicinal Chemistry, 2006, , 19-82. | 0.4 | 2 |
| 303 | Lessons learnt from structural studies of the oestrogen receptor. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 1-14. | 2.2 | 114 |
| 304 | Direct Association between the CREB-Binding Protein (CBP) and Nuclear Receptor Corepressor (N-CoR)â€. Biochemistry, 2006, 45, 13150-13162. | 1.2 | 16 |
| 305 | Macrophage/Cancer Cell Interactions Mediate Hormone Resistance by a Nuclear Receptor Derepression Pathway. Cell, 2006, 124, 615-629. | 13.5 | 237 |
| 306 | NCOR1 mRNA is an independent prognostic factor for breast cancer. Cancer Letters, 2006, 237, 123-129. | 3.2 | 28 |
| 307 | Structureâ€“function relationship of estrogen receptor Î± and Î²: Impact on human health. Molecular Aspects of Medicine, 2006, 27, 299-402. | 2.7 | 445 |
| 308 | Role of estrogen receptor Î± transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas, 2006, 54, 342-351. | 1.0 | 54 |
| 309 | Targeted mutation of key residues at the start of helix 12 in the hERÎ± ligand-binding domain identifies the role of hydrogen-bonding and hydrophobic interactions in the activity of the protein. Journal of Steroid Biochemistry and Molecular Biology, 2006, 98, 1-11. | 1.2 | 2 |
| 310 | Biomolecular markers of breast cancer. Frontiers in Bioscience - Landmark, 2006, 11, 1818. | 3.0 | 57 |
| 311 | A Tale of two Estrogen Receptors (ERs): How Differential ER-Estrogen Responsive Element Interactions Contribute to Subtype-Specific Transcriptional Responses. Nuclear Receptor Signaling, 2006, 4, nrs.04015. | 1.0 | 8 |
| 312 | Nuclear Receptor Corepressors and PPARÎ³. Nuclear Receptor Signaling, 2006, 4, nrs.04003. | 1.0 | 33 |
| 313 | Sequential Adjuvant Hormone Therapy in Postmenopausal Breast Cancer: Rationale and Clinical Results. International Journal of Biological Markers, 2006, 21, 111-122. | 0.7 | 0 |
| 314 | An NRSF/REST-like repressor downstream of Ebi/SMRTER/Su(H) regulates eye development in Drosophila. EMBO Journal, 2006, 25, 3191-3202. | 3.5 | 47 |
| 315 | Transcription in four dimensions: nuclear receptorâ€directed initiation of gene expression. EMBO Reports, 2006, 7, 161-167. | 2.0 | 169 |
| 316 | Bidirectional cross talk between ERÎ± and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment, 2006, 96, 131-146. | 1.1 | 133 |
| 317 | Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell, 2006, 10, 487-499. | 7.7 | 68 |
| 318 | Steroid Receptors and Their Role in the Biology and Control of Breast Cancer Growth. Seminars in Oncology, 2006, 33, 631-641. | 0.8 | 66 |
| 319 | Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. Journal of Cellular Biochemistry, 2006, 98, 1163-1184. | 1.2 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 320 | Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells. International Journal of Cancer, 2006, 118, 832-840. | 2.3 | 23 |
| 321 | PAX8-Peroxisome Proliferator-Activated Receptor Î³ (PPARÎ³) Disrupts Normal PAX8 or PPARÎ³ Transcriptional Function and Stimulates Follicular Thyroid Cell Growth. Endocrinology, 2006, 147, 367-376. | 1.4 | 60 |
| 322 | The Corepressors Silencing Mediator of Retinoid and Thyroid Hormone Receptor and Nuclear Receptor Corepressor Are Involved in Agonist- and Antagonist-Regulated Transcription by Androgen Receptor. Molecular Endocrinology, 2006, 20, 1048-1060. | 3.7 | 118 |
| 323 | Antagonist-Induced, Activation Function-2-Independent Estrogen Receptor Î± Phosphorylation. Molecular Endocrinology, 2006, 20, 516-533. | 3.7 | 16 |
| 324 | The G Protein-Coupled Receptor GPR30 Mediates the Proliferative Effects Induced by 17Î²-Estradiol and Hydroxytamoxifen in Endometrial Cancer Cells. Molecular Endocrinology, 2006, 20, 631-646. | 3.7 | 333 |
| 325 | Estrogen Receptors as Therapeutic Targets in Breast Cancer. Current Topics in Medicinal Chemistry, 2006, 6, 195-213. | 1.0 | 29 |
| 326 | Extranuclear expression of hormone receptors in primary breast cancer. Annals of Oncology, 2006, 17, 1213-1220. | 0.6 | 22 |
| 327 | ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors. Clinical Cancer Research, 2006, 12, 1008s-1012s. | 3.2 | 43 |
| 329 | Decreased Chicken Ovalbumin Upstream Promoter Transcription Factor II Expression in Tamoxifen-Resistant Breast Cancer Cells. Cancer Research, 2006, 66, 10188-10198. | 0.4 | 34 |
| 330 | Hormono-sensibilitÃ© et hormonorÃ©sistance aux anti-estrogÃ¨nes et inhibiteurs dâ€™aromatase. , 2006, , 371-383. | | 0 |
| 331 | Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches. Clinical Cancer Research, 2006, 12, 4790-4793. | 3.2 | 59 |
| 332 | 3-Phosphoinositide-Dependent Protein Kinase-1 Activates the Peroxisome Proliferator-Activated Receptor-Î³ and Promotes Adipocyte Differentiation. Molecular Endocrinology, 2006, 20, 268-278. | 3.7 | 34 |
| 333 | Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3100-3105. | 3.3 | 73 |
| 334 | Genetics and pharmacogenetics of estrogen response. Expert Review of Endocrinology and Metabolism, 2007, 2, 503-516. | 1.2 | 3 |
| 335 | Cellular Mechanisms of Endocrine Disruption. , 2007, , 135-174. | | 1 |
| 336 | Ajulemic Acid, a Synthetic Nonpsychoactive Cannabinoid Acid, Bound to the Ligand Binding Domain of the Human Peroxisome Proliferator-activated Receptor Î³. Journal of Biological Chemistry, 2007, 282, 18625-18633. | 1.6 | 58 |
| 337 | Structural Insights into Corepressor Recognition by Antagonist-bound Estrogen Receptors. Journal of Biological Chemistry, 2007, 282, 10449-10455. | 1.6 | 75 |
| 338 | Membrane-Initiated Actions of Estrogens in Neuroendocrinology: Emerging Principles. Endocrine Reviews, 2007, 28, 1-19. | 8.9 | 214 |

| # | Article | IF | Citations |
|---|---|---|---|
| 339 | Response of SMRT (Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor) and N-CoR (Nuclear Receptor Corepressor) Corepressors to Mitogen-Activated Protein Kinase Kinase Kinase Cascades Is Determined by Alternative mRNA Splicing. Molecular Endocrinology, 2007, 21, 1924-1939. | 3.7 | 34 |
| 340 | Progressive Loss of Estrogen Receptor Î± Cofactor Recruitment in Endocrine Resistance. Molecular Endocrinology, 2007, 21, 2615-2626. | 3.7 | 21 |
| 341 | Coactivators PGC-1Î² and SRC-1 Interact Functionally to Promote the Agonist Activity of the Selective Estrogen Receptor Modulator Tamoxifen. Journal of Biological Chemistry, 2007, 282, 26897-26907. | 1.6 | 24 |
| 342 | The Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor (SMRT) Corepressor Is Required for Full Estrogen Receptor Î± Transcriptional Activity. Molecular and Cellular Biology, 2007, 27, 5933-5948. | 1.1 | 85 |
| 343 | Breast Cancer Chemosensitivity. Advances in Experimental Medicine and Biology, 2007, , . | 0.8 | 2 |
| 344 | Molecularly Targeted Therapeutics for Breast Cancer. BioDrugs, 2007, 21, 215-224. | 2.2 | 15 |
| 345 | Estrogen Receptors in Resistance to Hormone Therapy. Advances in Experimental Medicine and Biology, 2007, 608, 130-143. | 0.8 | 50 |
| 346 | Overview of Resistance to Systemic Therapy in Patients with Breast Cancer. Advances in Experimental Medicine and Biology, 2007, 608, 1-22. | 0.8 | 721 |
| 348 | Estrogen Sensitivity of Target Genes and Expression of Nuclear Receptor Co-Regulators in Rat Prostate after Pre- and Postnatal Exposure to the Ultraviolet Filter 4-Methylbenzylidene Camphor. Environmental Health Perspectives, 2007, 115, 42-50. | 2.8 | 76 |
| 349 | Molecular Pharmacology of Estrogen and Progesterone Receptors. , 2007, , 17-28. | | 0 |
| 350 | Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. International Journal of Oncology, 2007, 31, 557-65. | 1.4 | 23 |
| 351 | Retinoids in biological control and cancer. Journal of Cellular Biochemistry, 2007, 102, 886-898. | 1.2 | 104 |
| 352 | Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression. Prostate, 2007, 67, 630-637. | 1.2 | 7 |
| 353 | Androgen receptorâ€mediated repression of novel target genes. Prostate, 2007, 67, 1371-1383. | 1.2 | 49 |
| 354 | Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene, 2007, 26, 1757-1768. | 2.6 | 74 |
| 355 | HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene, 2007, 26, 5439-5449. | 2.6 | 188 |
| 356 | Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nature Reviews Cancer, 2007, 7, 713-722. | 12.8 | 191 |
| 357 | Estrogen Receptors: How Do They Signal and What Are Their Targets. Physiological Reviews, 2007, 87, 905-931. | 13.1 | 1,489 |

| # | Article | IF | Citations |
|---|---|---|---|
| 358 | An overview of nuclear receptor coregulators involved in cerebellar development. Cerebellum, 2008, 7, 48-59. | 1.4 | 8 |
| 359 | Augmentation of estrogen receptor-mediated transcription by steroid and xenobiotic receptor. Endocrine, 2008, 33, 305-316. | 1.1 | 9 |
| 360 | Deregulation of cofactor of BRCA1 expression in breast cancer cells. Journal of Cellular Biochemistry, 2008, 103, 1798-1807. | 1.2 | 34 |
| 361 | Electromagnetic fields alter the expression of estrogen receptor cofactors in breast cancer cells. Bioelectromagnetics, 2008, 29, 169-176. | 0.9 | 54 |
| 362 | Differential expression of genes for transcription factors in theca and granulosa cells following selection of a dominant follicle in cattle. Molecular Reproduction and Development, 2008, 75, 904-914. | 1.0 | 23 |
| 363 | Non-genomic actions of estrogens and their interaction with genomic actions in the brain. Frontiers in Neuroendocrinology, 2008, 29, 238-257. | 2.5 | 303 |
| 364 | Minireview: Nuclear Receptors and Breast Cancer. Molecular Endocrinology, 2008, 22, 2215-2228. | 3.7 | 126 |
| 365 | Estrogen Receptor Pathways and Breast Cancer. , 2008, , 189-206. | | 2 |
| 367 | What are comparative studies telling us about the mechanism of ERÎ² action in the ERE-dependent E2 signaling pathway?. Journal of Steroid Biochemistry and Molecular Biology, 2008, 109, 266-272. | 1.2 | 7 |
| 368 | Involvement of ZIP/p62 in the regulation of PPARÎ± transcriptional activity by p38-MAPK. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 239-244. | 1.2 | 13 |
| 369 | Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance. Endocrine Reviews, 2008, 29, 217-233. | 8.9 | 470 |
| 370 | Interrogating the genome to understand oestrogen-receptor-mediated transcription. Expert Reviews in Molecular Medicine, 2008, 10, e10. | 1.6 | 9 |
| 373 | Regulation of Bone Cell Function by Estrogens. , 2008, , 383-423. | | 1 |
| 374 | Inhibition of GATA2-dependent transactivation of the TSHÎ² gene by ligand-bound estrogen receptor Î±. Journal of Endocrinology, 2008, 199, 113-125. | 1.2 | 15 |
| 375 | Nuclear Receptor Coregulators Differentially Modulate Induction and Glucocorticoid Receptor-Mediated Repression of the Corticotropin-Releasing Hormone Gene. Endocrinology, 2008, 149, 725-732. | 1.4 | 68 |
| 376 | Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT. Journal of Cell Biology, 2008, 183, 49-61. | 2.3 | 56 |
| 377 | Changes of Coregulators, MAP Kinase Activity and p27/kip1 with Estrogen or Antiestrogen Treatment in Breast Cancer Cell Line. Journal of Breast Cancer, 2008, 11, 56. | 0.8 | 0 |
| 378 | Genomics of Signaling Crosstalk of Estrogen Receptor Î± in Breast Cancer Cells. PLoS ONE, 2008, 3, e1859. | 1.1 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | PPARÎ³and PPARÎ´as Modulators of Neoplasia and Cell Fate. PPAR Research, 2008, 2008, 1-8. | 1.1 | 19 |
| 380 | Progesterone Action in Human Tissues: Regulation by Progesterone Receptor (PR) Isoform Expression, Nuclear Positioning and Coregulator Expression. Nuclear Receptor Signaling, 2009, 7, nrs.07009. | 1.0 | 139 |
| 381 | Autophagy facilitates the progression of ERÎ±-positive breast cancer cells to antiestrogen resistance. Autophagy, 2009, 5, 400-403. | 4.3 | 121 |
| 382 | Repression of the Estrogen Receptor-Î± Transcriptional Activity by the Rho/Megakaryoblastic Leukemia 1 Signaling Pathway. Journal of Biological Chemistry, 2009, 284, 33729-33739. | 1.6 | 18 |
| 383 | G Protein Pathway Suppressor 2 (GPS2) Is a Transcriptional Corepressor Important for Estrogen Receptor Î±-mediated Transcriptional Regulation. Journal of Biological Chemistry, 2009, 284, 36395-36404. | 1.6 | 43 |
| 384 | Gonadotropin-Releasing Hormone-Mediated Phosphorylation of Estrogen Receptor-Î± Contributes to fosB Expression in Mouse Gonadotrophs. Endocrinology, 2009, 150, 4583-4593. | 1.4 | 13 |
| 385 | Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 481-499. | 0.9 | 111 |
| 386 | The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer. Expert Opinion on Therapeutic Targets, 2009, 13, 665-674. | 1.5 | 29 |
| 388 | Corepressors, nuclear receptors, and epigenetic factors on DNA: A tail of repression. Psychoneuroendocrinology, 2009, 34, S39-S47. | 1.3 | 20 |
| 389 | Neuroactive steroids: An update of their roles in central and peripheral nervous system. Psychoneuroendocrinology, 2009, 34, S1-S8. | 1.3 | 44 |
| 390 | Expression of a phosphorylated p130<sup>Cas</sup> substrate domain attenuates the phosphatidylinositol 3â€kinase/Akt survival pathway in tamoxifen resistant breast cancer cells. Journal of Cellular Biochemistry, 2009, 107, 364-375. | 1.2 | 20 |
| 391 | Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer. Breast Cancer Research and Treatment, 2009, 116, 425-432. | 1.1 | 23 |
| 392 | New insights into the functions and regulation of the transcriptional corepressors SMRT and N-CoR. Cell Division, 2009, 4, 7. | 1.1 | 37 |
| 393 | Expression of estrogen receptor co-regulators SRC-1, RIP140 and NCoR and their interaction with estrogen receptor in rat uterus, under the influence of ormeloxifene. Journal of Steroid Biochemistry and Molecular Biology, 2009, 116, 93-101. | 1.2 | 10 |
| 394 | Transcriptional Coactivators and Corepressors in Endocrine Response and Resistance in Breast Cancer. , 2009, , 27-38. | | 0 |
| 395 | The Dark Side of Antihormonal Action in Breast Cancer. , 2009, , 63-84. | | 1 |
| 396 | Endocrine Resistance in Breast Cancer- Where Are We NowWith Intelligent Combination Therapies?. , 2009, , 175-194. | | 0 |
| 397 | The Epigenetics of Sex Differences in the Brain: Figure 1.. Journal of Neuroscience, 2009, 29, 12815-12823. | 1.7 | 389 |

| # | Article | IF | Citations |
|---|---|---|---|
| 398 | Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models. Anti-Cancer Drugs, 2009, 20, 51-58. | 0.7 | 11 |
| 399 | Overcoming Endocrine Resistance in Breast Cancer. Current Cancer Drug Targets, 2010, 10, 519-528. | 0.8 | 7 |
| 400 | Mechanisms of resistance to hormonal treatment in breast cancer. Clinical and Translational Oncology, 2010, 12, 246-252. | 1.2 | 13 |
| 401 | Prolactin and estradiol utilize distinct mechanisms to increase serine-118 phosphorylation and decrease levels of estrogen receptor Î± in T47D breast cancer cells. Breast Cancer Research and Treatment, 2010, 120, 369-377. | 1.1 | 15 |
| 402 | E-cadherin mediates the aggregation of breast cancer cells induced by tamoxifen and epidermal growth factor. Breast Cancer Research and Treatment, 2010, 121, 79-89. | 1.1 | 9 |
| 403 | Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Research and Treatment, 2010, 122, 395-407. | 1.1 | 46 |
| 404 | Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtypeâ€matched ductal and lobular carcinomas. Journal of Pathology, 2010, 222, 64-75. | 2.1 | 33 |
| 405 | Hakai acts as a coregulator of estrogen receptor alpha in breast cancer cells. Cancer Science, 2010, 101, 2019-2025. | 1.7 | 22 |
| 406 | Modulation of Soluble Receptor Signaling by Coregulators. , 2010, , 183-206. | | 0 |
| 407 | Deletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane disease. Journal of Inflammation Research, 2010, 3, 127. | 1.6 | 5 |
| 408 | Estrogen Receptors Recruit SMRT and N-CoR Corepressors through Newly Recognized Contacts between the Corepressor N Terminus and the Receptor DNA Binding Domain. Molecular and Cellular Biology, 2010, 30, 1434-1445. | 1.1 | 37 |
| 409 | Proteasomal degradation of retinoid X receptor Î± reprograms transcriptional activity of PPARÎ³ in obese mice and humans. Journal of Clinical Investigation, 2010, 120, 1454-1468. | 3.9 | 56 |
| 410 | Estrogen Receptor Regulates E2F1 Expression to Mediate Tamoxifen Resistance. Molecular Cancer Research, 2010, 8, 343-352. | 1.5 | 41 |
| 411 | The Nuclear Receptor Corepressor Has Organizational Effects within the Developing Amygdala on Juvenile Social Play and Anxiety-Like Behavior. Endocrinology, 2010, 151, 1212-1220. | 1.4 | 50 |
| 412 | Cooperative Activation of Cyclin D1 and Progesterone Receptor Gene Expression by the SRC-3 Coactivator and SMRT Corepressor. Molecular Endocrinology, 2010, 24, 1187-1202. | 3.7 | 30 |
| 413 | Melatonin inhibits mitogenic cross-talk between retinoic acid-related orphan receptor alpha (RORÎ±) and ERÎ± in MCF-7 human breast cancer cells. Steroids, 2010, 75, 944-951. | 0.8 | 25 |
| 414 | Application of Aptamers in Food Safety. Chinese Journal of Analytical Chemistry, 2011, 39, 925-933. | 0.9 | 13 |
| 415 | Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). International Journal of Oncology, 2011, 38, 1197-217. | 1.4 | 59 |

| # | Article | IF | Citations |
|---|---|---|---|
| 416 | Antiestrogens and Their Therapeutic Applications in Breast Cancer and Other Diseases. Annual Review of Medicine, 2011, 62, 217-232. | 5.0 | 74 |
| 417 | Epigenetic organization of brain sex differences and juvenile social play behavior. Hormones and Behavior, 2011, 59, 358-363. | 1.0 | 37 |
| 418 | Glucocorticoid-independent Repression of Tumor Necrosis Factor (TNF) Î±-stimulated Interleukin (IL)-6 Expression by the Glucocorticoid Receptor. Journal of Biological Chemistry, 2011, 286, 19297-19310. | 1.6 | 43 |
| 419 | Thyroid hormone receptor Î²1 domains responsible for the antagonism with the ras oncogene: role of corepressors. Oncogene, 2011, 30, 854-864. | 2.6 | 23 |
| 420 | HEXIM1 is a critical determinant of the response to tamoxifen. Oncogene, 2011, 30, 3563-3569. | 2.6 | 22 |
| 421 | FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth. Journal of Cellular and Molecular Medicine, 2011, 15, 72-85. | 1.6 | 52 |
| 422 | Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast, 2011, 20, S42-S49. | 0.9 | 82 |
| 423 | Mechanisms of Endocrine Resistance in Breast Cancer. Annual Review of Medicine, 2011, 62, 233-247. | 5.0 | 963 |
| 424 | Transient over-expression of estrogen receptor-Î± in breast cancer cells promotes cell survival and estrogen-independent growth. Breast Cancer Research and Treatment, 2011, 128, 357-368. | 1.1 | 23 |
| 425 | Acquisition of Sexual Receptivity: Roles of Chromatin Acetylation, Estrogen Receptor-Î±, and Ovarian Hormones. Endocrinology, 2011, 152, 3172-3181. | 1.4 | 30 |
| 426 | Sex differences in epigenetic mechanisms may underlie risk and resilience for mental health disorders. Epigenetics, 2011, 6, 857-861. | 1.3 | 56 |
| 427 | Visualization of Estrogen Receptor Transcriptional Activation in Zebrafish. Endocrinology, 2011, 152, 2690-2703. | 1.4 | 79 |
| 428 | Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics, 2011, 3, 451-470. | 1.0 | 32 |
| 429 | Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis. Journal of Cell Biology, 2011, 192, 55-67. | 2.3 | 40 |
| 430 | Sexually Selected Traits: A Fundamental Framework for Studies on Behavioral Epigenetics. ILAR Journal, 2012, 53, 253-269. | 1.8 | 27 |
| 431 | Role of SUMOylation in Full Antiestrogenicity. Molecular and Cellular Biology, 2012, 32, 3823-3837. | 1.1 | 23 |
| 432 | Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene, 2012, 31, 4353-4361. | 2.6 | 26 |
| 433 | Binding of the N-terminal Region of Coactivator TIF2 to the Intrinsically Disordered AF1 Domain of the Glucocorticoid Receptor Is Accompanied by Conformational Reorganizations. Journal of Biological Chemistry, 2012, 287, 44546-44560. | 1.6 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 435 | Estradiol receptors in breast cancer cells: Associated co-factors as targets for new therapeutic approaches. Steroids, 2012, 77, 1249-1261. | 0.8 | 27 |
| 437 | Nuclear hormone receptors in podocytes. Cell and Bioscience, 2012, 2, 33. | 2.1 | 13 |
| 438 | Î±NAC interacts with histone deacetylase corepressors to control Myogenin and Osteocalcin gene expression. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2012, 1819, 1208-1216. | 0.9 | 9 |
| 439 | The ligand-mediated nuclear mobility and interaction with estrogen-responsive elements of estrogen receptors are subtype specific. Journal of Molecular Endocrinology, 2012, 49, 249-266. | 1.1 | 11 |
| 440 | Tamoxifen-Induced Epigenetic Silencing of Oestrogen-Regulated Genes in Anti-Hormone Resistant Breast Cancer. PLoS ONE, 2012, 7, e40466. | 1.1 | 54 |
| 441 | Estrogenic Regulation of the GnRH Neuron. Frontiers in Endocrinology, 2012, 3, 52. | 1.5 | 70 |
| 442 | Promise and failure of targeted therapy in breast cancer. Frontiers in Bioscience - Scholar, 2012, S4, 356. | 0.8 | 2 |
| 443 | Tamoxifen Resistance in Breast Cancer. Biomolecules and Therapeutics, 2012, 20, 256-267. | 1.1 | 213 |
| 444 | Steroid receptor coactivators 1, 2, and 3: Critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Molecular and Cellular Endocrinology, 2012, 348, 430-439. | 1.6 | 141 |
| 445 | ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Medicinal Research Reviews, 2012, 32, 166-215. | 5.0 | 72 |
| 446 | Zinc finger protein 131 inhibits estrogen signaling by suppressing estrogen receptor Î± homo-dimerization. Biochemical and Biophysical Research Communications, 2013, 430, 400-405. | 1.0 | 8 |
| 447 | Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance. International Journal of Molecular Sciences, 2013, 14, 108-145. | 1.8 | 203 |
| 448 | Negative regulation of ERÎ± by a novel protein CAC1 through association with histone demethylase LSD1. FEBS Letters, 2013, 587, 17-22. | 1.3 | 18 |
| 449 | Derailed Estrogen Signaling and Breast Cancer: An Authentic Couple. Endocrine Reviews, 2013, 34, 1-32. | 8.9 | 104 |
| 450 | Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells. European Journal of Pharmaceutical Sciences, 2013, 50, 181-190. | 1.9 | 12 |
| 451 | Sex Hormone Receptors in Breast Cancer. Vitamins and Hormones, 2013, 93, 99-133. | 0.7 | 10 |
| 452 | Modulation of Estrogen Receptor Alpha Activity and Expression During Breast Cancer Progression. Vitamins and Hormones, 2013, 93, 135-160. | 0.7 | 24 |
| 453 | SpliceArray Profiling of Breast Cancer Reveals a Novel Variant of NCOR2/SMRT That Is Associated with Tamoxifen Resistance and Control of ERÎ± Transcriptional Activity. Cancer Research, 2013, 73, 246-255. | 0.4 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 454 | KDM4B is a Master Regulator of the Estrogen Receptor Signalling Cascade. Nucleic Acids Research, 2013, 41, 6892-6904. | 6.5 | 66 |
| 455 | Class I Lysine Deacetylases Facilitate Glucocorticoid-induced Transcription. Journal of Biological Chemistry, 2013, 288, 28900-28912. | 1.6 | 21 |
| 456 | COREGULATORS AND THEIR ROLE IN SELECTIVE ESTROGEN RECEPTOR MODULATOR ACTION. , 2013, , 153-173. | | 0 |
| 457 | The normal human ovary part II: how steroid hormones work. , 0, , 37-64. | | 2 |
| 458 | Selective estrogen receptor modulators: tissue specificity and clinical utility. Clinical Interventions in Aging, 2014, 9, 1437. | 1.3 | 157 |
| 459 | Bisphenol a regulates the estrogen receptor alpha signaling in developing hippocampus of male rats through estrogen receptor. Hippocampus, 2014, 24, 1570-1580. | 0.9 | 48 |
| 460 | Minireview: The Versatile Roles of Lysine Deacetylases in Steroid Receptor Signaling. Molecular Endocrinology, 2014, 28, 607-621. | 3.7 | 5 |
| 462 | Emergence of Constitutively Active Estrogen Receptor-Î± Mutations in Pretreated Advanced Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 1757-1767. | 3.2 | 529 |
| 463 | Tristetraprolin Represses Estrogen Receptor Î± Transactivation in Breast Cancer Cells. Journal of Biological Chemistry, 2014, 289, 15554-15565. | 1.6 | 18 |
| 464 | Low levels of 3,3â€²-diindolylmethane activate estrogen receptor Î± and induce proliferation of breast cancer cells in the absence of estradiol. BMC Cancer, 2014, 14, 524. | 1.1 | 36 |
| 465 | Nuclear receptor modulation â€“ Role of coregulators in selective estrogen receptor modulator (SERM) actions. Steroids, 2014, 90, 39-43. | 0.8 | 46 |
| 466 | Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha. Journal of Molecular Modeling, 2014, 20, 2338. | 0.8 | 8 |
| 467 | Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor Î±. International Journal of Oncology, 2014, 45, 2167-2175. | 1.4 | 16 |
| 468 | Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review). Oncology Reports, 2014, 32, 3-15. | 1.2 | 135 |
| 469 | MDC1 Enhances Estrogen Receptor-mediated Transactivation and Contributes to Breast Cancer Suppression. International Journal of Biological Sciences, 2015, 11, 992-1005. | 2.6 | 32 |
| 470 | Optimizing the Use of Neoadjuvant Endocrine Therapy. Current Oncology Reports, 2015, 17, 33. | 1.8 | 2 |
| 471 | SIAH ubiquitin ligases regulate breast cancer cell migration and invasion independent of the oxygen status. Cell Cycle, 2015, 14, 3734-3747. | 1.3 | 25 |
| 472 | Estrogen-related Receptor Î² Reduces the Subnuclear Mobility of Estrogen Receptor Î± and Suppresses Estrogen-dependent Cellular Function. Journal of Biological Chemistry, 2015, 290, 12332-12345. | 1.6 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 473 | The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. Nucleic Acids Research, 2015, 43, 196-207. | 6.5 | 86 |
| 474 | The changing role of ER in endocrine resistance. Breast, 2015, 24, S60-S66. | 0.9 | 97 |
| 475 | Roles for miRNAs in endocrine resistance in breast cancer. Endocrine-Related Cancer, 2015, 22, R279-R300. | 1.6 | 63 |
| 476 | Perinatal Neurohormonal Programming and Endocrine Disruption. , 2016, , 63-87. | | 1 |
| 477 | PPARÎ´as a Metabolic Initiator of Mammary Neoplasia and Immune Tolerance. PPAR Research, 2016, 2016, 1-7. | 1.1 | 6 |
| 478 | Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer. International Journal of Molecular Sciences, 2016, 17, 1434. | 1.8 | 35 |
| 479 | Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer. Steroids, 2016, 114, 41-47. | 0.8 | 29 |
| 480 | LSD1 engages a corepressor complex for the activation of the estrogen receptor Î± by estrogen and cAMP. Nucleic Acids Research, 2016, 44, 8655-8670. | 6.5 | 62 |
| 481 | Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem. Medical Principles and Practice, 2016, 25, 28-40. | 1.1 | 28 |
| 483 | Neuroepigenetics of Sexual Differentiation of Brain and Behavior. Epigenetics and Human Health, 2016, , 209-232. | 0.2 | 0 |
| 484 | Minireview: The Link Between ERÎ± Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer. Molecular Endocrinology, 2016, 30, 965-976. | 3.7 | 48 |
| 485 | Discovery at the interface: Toward novel anti-proliferative agents targeting human estrogen receptor/S100 interactions. Cell Cycle, 2016, 15, 2806-2818. | 1.3 | 5 |
| 486 | COPS5 amplification and overexpression confers tamoxifen-resistance in ERÎ±-positive breast cancer by degradation of NCoR. Nature Communications, 2016, 7, 12044. | 5.8 | 56 |
| 487 | Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clinical Cancer Research, 2016, 22, 3937-3949. | 3.2 | 24 |
| 488 | Rhodiola crenulata induces an early estrogenic response and reduces proliferation and tumorsphere formation over time in MCF7 breast cancer cells. Phytomedicine, 2016, 23, 87-94. | 2.3 | 31 |
| 489 | PDCD2 and NCoR1 as putative tumor suppressors in gastric gastrointestinal stromal tumors. Cellular Oncology (Dordrecht), 2016, 39, 129-137. | 2.1 | 16 |
| 490 | FOXO factors and breast cancer: outfoxing endocrine resistance. Endocrine-Related Cancer, 2016, 23, R113-R130. | 1.6 | 39 |
| 491 | Estrogen and Progesterone Action. , 2016, , 2207-2215.e3. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 493 | Characterisation of the transcriptome of male and female wild-type guppy brains with RNA-Seq and consequences of exposure to the pharmaceutical pollutant, 17Î±-ethinyl estradiol. Aquatic Toxicology, 2017, 186, 28-39. | 1.9 | 15 |
| 494 | Fatty acid synthase regulates estrogen receptor-Î± signaling in breast cancer cells. Oncogenesis, 2017, 6, e299-e299. | 2.1 | 67 |
| 495 | Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications. Physiological Reviews, 2017, 97, 1045-1087. | 13.1 | 283 |
| 496 | Nuclear and Membrane Actions of Estrogen Receptor Alpha: Contribution to the Regulation of Energy and Glucose Homeostasis. Advances in Experimental Medicine and Biology, 2017, 1043, 401-426. | 0.8 | 12 |
| 497 | Antiestrogens: structure-activity relationships and use in breast cancer treatment. Journal of Molecular Endocrinology, 2017, 58, R15-R31. | 1.1 | 66 |
| 498 | Naringenin Inhibits Proliferation and Survival of Tamoxifenâ€•Resistant Breast Cancer Cells. , 0, , . | | 4 |
| 499 | Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. , 2018, 186, 1-24. | | 297 |
| 500 | Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2â€“ERÎ±â€“GREB1 Transcriptional Axis. Cancer Research, 2018, 78, 671-684. | 0.4 | 80 |
| 501 | Modulation of Soluble Receptor Signaling by Coregulators. , 2018, , 55-75. | | 0 |
| 502 | Identification and Molecular Characterization of HOS15-interacting Proteins in Arabidopsis thaliana. Journal of Plant Biology, 2018, 61, 336-345. | 0.9 | 22 |
| 503 | Exploring Proteinâ€“Protein Interaction in the Study of Hormone-Dependent Cancers. International Journal of Molecular Sciences, 2018, 19, 3173. | 1.8 | 19 |
| 504 | Chemotherapeutic resistance: a nano-mechanical point of view. Biological Chemistry, 2018, 399, 1433-1446. | 1.2 | 18 |
| 505 | PPARÎ³ Expression Is Diminished in Macrophages of Recurrent Miscarriage Placentas. International Journal of Molecular Sciences, 2018, 19, 1872. | 1.8 | 28 |
| 506 | KRAB-containing zinc finger protein ZNF496 inhibits breast cancer cell proliferation by selectively repressing ERÎ± activity. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2018, 1861, 841-853. | 0.9 | 9 |
| 507 | Nuclear receptors: recent drug discovery for cancer therapies. Endocrine Reviews, 2019, 40, 1207-1249. | 8.9 | 65 |
| 508 | The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer. Cancers, 2019, 11, 1122. | 1.7 | 14 |
| 509 | Flow cytometry-based FRET identifies binding intensities in PPARÎ³1 protein-protein interactions in living cells. Theranostics, 2019, 9, 5444-5463. | 4.6 | 6 |
| 510 | The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View. Cells, 2019, 8, 1280. | 1.8 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 511 | Pathways to Endocrine Therapy Resistance in Breast Cancer. Frontiers in Endocrinology, 2019, 10, 573. | 1.5 | 100 |
| 512 | Hox genes: Downstream â€œeffectorsâ€•of retinoic acid signaling in vertebrate embryogenesis. Genesis, 2019, 57, e23306. | 0.8 | 45 |
| 513 | Nuclear Receptors Are Differentially Expressed and Activated in KAIMRC1 Compared to MCF7 and MDA-MB231 Breast Cancer Cells. Molecules, 2019, 24, 2028. | 1.7 | 7 |
| 514 | Estrogen signaling: An emanating therapeutic target for breast cancer treatment. European Journal of Medicinal Chemistry, 2019, 177, 116-143. | 2.6 | 82 |
| 515 | Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 161-170. | 1.2 | 108 |
| 516 | SNP mutationâ€•related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database. Cancer Medicine, 2019, 8, 2303-2312. | 1.3 | 31 |
| 517 | Toxicity, cytotoxicity and biological activities of seeds of Carapa procera (DC), a native oil tree. International Journal of Biological and Chemical Sciences, 2019, 13, 49. | 0.1 | 2 |
| 518 | An occult urothelial carcinoma with wide multiorgan metastases and its genetic alteration profiling. Medicine (United States), 2019, 98, e15245. | 0.4 | 4 |
| 519 | Estrogen Receptor and Breast Cancer. Cancer Drug Discovery and Development, 2019, , . | 0.2 | 4 |
| 520 | Molecular Mechanisms of Endocrine Resistance. Cancer Drug Discovery and Development, 2019, , 265-307. | 0.2 | 5 |
| 521 | GPER and ERÎ± mediate estradiol enhancement of mitochondrial function in inflamed adipocytes through a PKA dependent mechanism. Journal of Steroid Biochemistry and Molecular Biology, 2019, 185, 256-267. | 1.2 | 18 |
| 522 | Selective estrogen receptor modulators (SERMS): keys to understanding their function. Menopause, 2020, 27, 1171-1176. | 0.8 | 15 |
| 523 | Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer. Journal of Medicinal Chemistry, 2020, 63, 15094-15114. | 2.9 | 52 |
| 524 | IFI27/ISG12 Downregulates Estrogen Receptor Î± Transactivation by Facilitating Its Interaction With CRM1/XPO1 in Breast Cancer Cells. Frontiers in Endocrinology, 2020, 11, 568375. | 1.5 | 15 |
| 525 | Targeting mutated estrogen receptor alpha: Rediscovering old and identifying new therapeutic strategies in metastatic breast cancer treatment. Current Opinion in Endocrine and Metabolic Research, 2020, 15, 43-48. | 0.6 | 3 |
| 526 | Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment. Cancer Research, 2021, 81, 371-383. | 0.4 | 10 |
| 527 | In-silico identification of potential inhibitors targeting the DNA binding domain of estrogen receptor Î± for the treatment of hormone therapy-resistant breast cancer. Journal of Biomolecular Structure and Dynamics, 2022, 40, 5203-5210. | 2.0 | 4 |
| 528 | Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview. Endocrine-Related Cancer, 2021, 28, R31-R46. | 1.6 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 529 | Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer. Frontiers in Endocrinology, 2021, 12, 599586. | 1.5 | 44 |
| 530 | Tristetraprolin: A cytosolic regulator of mRNA turnover moonlighting as transcriptional corepressor of gene expression. Molecular Genetics and Metabolism, 2021, 133, 137-147. | 0.5 | 4 |
| 531 | Nuclear translocation of MRTFA in MCF7 breast cancer cells shifts ERÎ± nuclear/genomic to extra-nuclear/non genomic actions. Molecular and Cellular Endocrinology, 2021, 530, 111282. | 1.6 | 7 |
| 532 | Hormone Resistance. Cancer Treatment and Research, 2009, 147, 1-33. | 0.2 | 2 |
| 533 | Dynamics of Estrogen Receptor-mediated Transcriptional Activation of Responsive Genes In Vivo: Apprehending Transcription in Four Dimensions. Advances in Experimental Medicine and Biology, 2008, 617, 129-138. | 0.8 | 18 |
| 534 | Selective Estrogen Modulators as an Anticancer Tool:. Advances in Experimental Medicine and Biology, 2008, 630, 206-219. | 0.8 | 48 |
| 536 | Novel Approaches to Controlling Transcription. , 2002, 24, 137-178. | | 4 |
| 537 | Estrogen Action and Breast Cancer. , 2004, , 317-358. | | 1 |
| 538 | Clinical Approaches to Discovering and Testing New Breast Cancer Prevention Drugs. , 2005, , 213-237. | | 5 |
| 539 | Corepressors and Nuclear Hormone Receptor Function. Current Topics in Microbiology and Immunology, 2001, 254, 101-116. | 0.7 | 72 |
| 540 | Regulation of SMRT and N-CoR Corepressor Function. Current Topics in Microbiology and Immunology, 2001, 254, 117-136. | 0.7 | 41 |
| 541 | Regulation of NF-ÐºB by Glucocorticoids. , 2003, , 221-239. | | 1 |
| 542 | Regulation of Bone Cell Function by Estrogens. , 2001, , 305-337. | | 6 |
| 544 | A Hox gene regulatory network for hindbrain segmentation. Current Topics in Developmental Biology, 2020, 139, 169-203. | 1.0 | 42 |
| 545 | An overview of nuclear receptor coregulators involved in cerebellar development. Cerebellum, 2008, 7, 1-12. | 1.4 | 2 |
| 546 | Troglitazone Inhibits Mitogenic Signaling by Insulin in Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2000, 35, 749-757. | 0.8 | 33 |
| 547 | itamin D and regulation of gene expression. Current Opinion in Clinical Nutrition and Metabolic Care, 1998, 1, 347-354. | 1.3 | 47 |
| 548 | Molecular determinants of nuclear receptor-corepressor interaction. Genes and Development, 1999, 13, 3198-3208. | 2.7 | 455 |

| # | Article | IF | Citations |
|---|---|---|---|
| 549 | The coregulator exchange in transcriptional functions of nuclear receptors. Genes and Development, 2000, 14, 121-141. | 2.7 | 1,810 |
| 550 | The Mad Protein Family Links Transcriptional Repression to Cell Differentiation. Cold Spring Harbor Symposia on Quantitative Biology, 1998, 63, 423-434. | 2.0 | 49 |
| 551 | Estrogen Signaling: A Subtle Balance Between ERÂ and ERÂ. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2003, 3, 281-292. | 3.4 | 726 |
| 552 | Coregulators in Nuclear Estrogen Receptor Action: From Concept to Therapeutic Targeting. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2005, 5, 343-357. | 3.4 | 273 |
| 553 | The Fight Against Tamoxifen Resistance in Breast Cancer Therapy: A New Target in the Battle?. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2007, 7, 13-16. | 3.4 | 2 |
| 554 | The Importance of the Estrogen Receptor in Breast Cancer. , 2002, , 149-186. | | 9 |
| 555 | Differential Gene Regulation by PPARÂ Agonist and Constitutively Active PPARÂ2. Molecular Endocrinology, 2002, 16, 1040-1048. | 3.7 | 41 |
| 556 | Prolactin Modulation of Immune and Inflammatory Responses. Endocrine Reviews, 2002, 57, 435-455. | 7.1 | 177 |
| 557 | Biological roles and mechanistic actions of co-repressor complexes. Journal of Cell Science, 2002, 115, 689-698. | 1.2 | 278 |
| 558 | The ETS Family Member TEL Binds to Nuclear Receptors RAR and RXR and Represses Gene Activation. PLoS ONE, 2011, 6, e23620. | 1.1 | 6 |
| 559 | Hormone Therapy for Metastatic Breast Cancer. Korean Journal of Medicine, 2017, 92, 251-258. | 0.1 | 1 |
| 560 | The role of Siah2 in tumorigenesis and cancer therapy. Gene, 2022, 809, 146028. | 1.0 | 12 |
| 561 | Thyroid Hormone Receptor Family Members. , 2000, , 135-151. | | 0 |
| 562 | Applications of developmental biology to medicine and animal agriculture. , 2000, 54, 213-256. | | 0 |
| 564 | Coactivators and Corepressors. , 2001, , 389-408. | | 0 |
| 565 | The Androgen Receptor. , 2001, , 137-177. | | 1 |
| 567 | ER. , 2002, , 308-335. | | 0 |
| 568 | Androgen Receptor Interacting Proteins: Co-Activators And Co-Repressors. , 2002, , 91-138. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 569 | Peroxisome proliferator-activated receptors: Lipid binding proteins controling gene expression. , 2002, , 131-138. | | 21 |
| 570 | SERM Modulation of Gene Expression. , 2002, , 57-76. | | 0 |
| 571 | Transcriptional Control of the Development and Function of the Hypothalamic-Pituitary Axis. , 2002, , 3-39. | | 0 |
| 572 | The Breast Cancer Phenotype and Endocrine Response. , 2002, , 301-342. | | 1 |
| 573 | Corepressors in Mediating Repression by Nuclear Receptors. , 2003, , 29-33. | | 0 |
| 577 | New Molecular Therapeutic Interventions: The Case of Breast Cancers. , 2010, , 571-611. | | 0 |
| 579 | Estrogen and Progesterone Action. , 2010, , 2318-2326. | | 1 |
| 580 | Structural Insights into Estrogen Receptors and Antiestrogen Therapies. Cancer Drug Discovery and Development, 2019, , 241-263. | 0.2 | 0 |
| 581 | Contribution of HDAC3 to transcriptional repression by the human papillomavirus 31 E8^E2 protein. Journal of General Virology, 2020, 101, 751-759. | 1.3 | 6 |
| 582 | Challenges and Opportunities of Genomic Approaches in Therapeutics Development. Methods in Molecular Biology, 2021, 2194, 107-126. | 0.4 | 2 |
| 583 | Segregation of nuclear and membrane-initiated actions of estrogen receptor using genetically modified animals and pharmacological tools. Molecular and Cellular Endocrinology, 2022, 539, 111467. | 1.6 | 6 |
| 585 | Mechanisms of Resistance to Hormone Therapy. , 2006, , 805-821. | | 0 |
| 588 | Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cellular and Molecular Life Sciences, 2014, 71, 1549. | 2.4 | 14 |
| 589 | Peroxisome proliferator-activated receptors: lipid binding proteins controling gene expression. Molecular and Cellular Biochemistry, 2002, 239, 131-8. | 1.4 | 21 |
| 592 | Nuclear Receptor Coregulators in Hormone-Dependent Cancers. Cancers, 2022, 14, 2402. | 1.7 | 4 |
| 593 | Functions of Papillomavirus E8^E2 Proteins in Tissue Culture and In Vivo. Viruses, 2022, 14, 953. | 1.5 | 4 |
| 594 | Exploring new pathways in endocrine-resistant breast cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 337-361. | 0.5 | 2 |
| 595 | Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer. Oncogene, 2022, 41, 3705-3718. | 2.6 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 596 | Transcriptional Repression of Aerobic Glycolysis by OVOL2 in Breast Cancer. Advanced Science, 2022, 9, . | 5.6 | 6 |
| 597 | Epigenetic factors in breast cancer therapy. Frontiers in Genetics, 0, 13, . | 1.1 | 1 |
| 598 | The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens. Journal of Biological Chemistry, 2023, 299, 102757. | 1.6 | 4 |
| 599 | Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis. Nature Communications, 2022, 13, . | 5.8 | 5 |
| 600 | Acetylation of nuclear receptors in health and disease: an update. FEBS Journal, 2024, 291, 217-236. | 2.2 | 5 |
| 601 | Diabetes Mellitus and iPSC-Based Therapy. , 2023, , 225-246. | | 0 |